NeoGenomics, Inc. (NEO)

NASDAQ: NEO · IEX Real-Time Price · USD
12.30
-0.21 (-1.68%)
At close: Sep 29, 2023, 4:00 PM
12.72
+0.42 (3.41%)
After-hours: Sep 29, 2023, 6:35 PM EDT
-1.68%
Market Cap 1.57B
Revenue (ttm) 551.62M
Net Income (ttm) -114.67M
Shares Out 127.55M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE 222.22
Dividend n/a
Ex-Dividend Date n/a
Volume 1,478,838
Open 12.67
Previous Close 12.51
Day's Range 11.90 - 12.68
52-Week Range 6.00 - 20.54
Beta 1.08
Analysts Buy
Price Target 19.33 (+57.15%)
Earnings Date Nov 7, 2023

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence ... [Read more]

Sector Healthcare
IPO Date Nov 2, 1999
Employees 2,100
Stock Exchange NASDAQ
Ticker Symbol NEO
Full Company Profile

Financial Performance

In 2022, NeoGenomics's revenue was $509.73 million, an increase of 5.24% compared to the previous year's $484.33 million. Losses were -$144.25 million, 1628.2% more than in 2021.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for NEO stock is "Buy." The 12-month stock price forecast is $19.33, which is an increase of 57.15% from the latest price.

Price Target
$19.33
(57.15% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NeoGenomics Reports Second Quarter 2023 Results

Second Quarter Revenue Increased 18% to $147 Million FORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today a...

7 weeks ago - Accesswire

NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has co...

2 months ago - Accesswire

NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023

FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its secon...

2 months ago - Accesswire

Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery

PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION 18 July 202 3 , 7:00 AM CE S T

2 months ago - GlobeNewsWire

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth ...

3 months ago - Accesswire

NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that its RaDaR® assay, a pers...

3 months ago - Accesswire

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaD...

4 months ago - Accesswire

NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

4 months ago - Accesswire

NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its cancer...

4 months ago - Accesswire

NeoGenomics Reports First Quarter 2023 Results

First Quarter Revenue Increased 17% to $137 Million FORT MYERS, FL / ACCESSWIRE / May 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing se...

5 months ago - Accesswire

NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference

FT. MYERS, FL / ACCESSWIRE / May 3, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

5 months ago - Accesswire

NeoGenomics to Announce First Quarter 2023 Financial Results

FT. MYERS, FL / ACCESSWIRE / April 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it will release its fir...

5 months ago - Accesswire

NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference

FT. MYERS, FL / ACCESSWIRE / April 11, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announ...

6 months ago - Accesswire

NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023

FT. MYERS, FL / ACCESSWIRE / April 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the company and its coll...

6 months ago - Accesswire

NeoGenomics to Host Investor Day on April 4, 2023

FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the Company will host a...

6 months ago - Accesswire

Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

FT. MYERS, Fla. & NEW YORK--(BUSINESS WIRE)-- #AI--Massive Bio, Inc., a private AI-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and NeoGenomics,...

6 months ago - Business Wire

NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test

FT MYERS, FL / ACCESSWIRE / March 16, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability o...

7 months ago - Accesswire

NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP

FT. MYERS, FL / ACCESSWIRE / March 13, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the expansion of their next-...

7 months ago - Accesswire

NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference

FT. MYERS, FL / ACCESSWIRE / February 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today ann...

7 months ago - Accesswire

NeoGenomics Reports Fourth Quarter and Full Year 2022 Results

Fourth Quarter Revenue Increased 10% to $139 million; Full Year Revenue Increased 5% to $510 million FORT MYERS, FL / ACCESSWIRE / February 23, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company") , ...

7 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of NeoGenomics Laboratories, Inc. (NEO) Investigation

NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeoGenomics Laboratories, Inc. ("NeoGenomics" or "the ...

8 months ago - Business Wire

NEO IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages NeoGenomics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 6 Deadline in Securities Class Action - NEO

NEW YORK , Feb. 7, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NeoGenomics, Inc. (NASDAQ: NEO) between February 27, 2020 and Ap...

8 months ago - PRNewsWire

NeoGenomics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 6, 2023 to Discuss Your Rights - NEO

New York, New York--(Newsfile Corp. - February 6, 2023) - Levi & Korsinsky, LLP notifies investors in NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) of a class action securities laws...

8 months ago - Newsfile Corp

RaDaR(R) Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery

Newly-published data shows a strong link between tumor DNA circulating in blood and patient responses to investigational neoadjuvant treatment with immune therapies FT. MYERS, FL / ACCESSWIRE / Februa...

8 months ago - Accesswire

NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023

FT. MYERS, FL / ACCESSWIRE / February 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it plans to release i...

8 months ago - Accesswire